Eledon Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Eledon Pharmaceuticals, Inc. carries a market capitalization of 183.66M, placing it among publicly traded companies globally. Its enterprise value stands at 230.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 183.66M |
| Enterprise Value | 230.42M |
Share Statistics
Eledon Pharmaceuticals, Inc. currently has 80.89M shares outstanding.
| Shares Outstanding | 80.89M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 9.65 |
| P/TBV Ratio | 508.31 |
| P/FCF Ratio | -5.39 |
| P/OCF Ratio | -5.39 |
Financial Position
Eledon Pharmaceuticals, Inc. maintains a current ratio of 7.90, meaning it holds 7.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.90 |
| Quick Ratio | 7.56 |
| Debt / Equity | 1.41 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -233.18 |
| Return on Assets (ROA) | -72.74 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Eledon Pharmaceuticals, Inc.'s stock has declined approximately -35.42571% over the past 52 weeks. The 50-day moving average sits at 2.89, while the 200-day moving average is 3.07.
| Beta (5Y) | N/A |
| 52-Week Price Change | -35.42571% |
| 50-Day Moving Average | 2.89 |
| 200-Day Moving Average | 3.07 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -84.52M, while operating income came in at -84.60M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -84.60M |
| Pretax Income | -98.53M |
| Net Income | -98.56M |
| EBITDA | -84.52M |
| EBIT | -84.60M |
| Earnings Per Share (EPS) | -0.98 |
Balance Sheet
Eledon Pharmaceuticals, Inc. holds 88.76M in cash and equivalents against 467,000.00 in total debt, resulting in a net debt position of -6.80M. Total book value stands at 33.01M, with working capital of 81.30M providing operational flexibility.
| Cash & Cash Equivalents | 88.76M |
| Total Debt | 467,000.00 |
| Net Debt | -6.80M |
| Equity (Book Value) | 33.01M |
| Book Value Per Share | 0.41 |
| Working Capital | 81.30M |
Cash Flow
Eledon Pharmaceuticals, Inc. produced -73.86M in operating cash flow over the past twelve months.
| Operating Cash Flow | -73.86M |
| Capital Expenditures | N/A |
| Free Cash Flow | -73.86M |
| FCF Per Share | -0.73 |
Dividends & Yields
The company's payout ratio of -1.43 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | -1.43 |
| Shareholder Yield | -16.88 |
| FCF Yield | -18.55 |
Stock Splits
Eledon Pharmaceuticals, Inc.'s most recent stock split took place on October 5, 2020 with a 18:1 split ratio.
| Last Split Date | 10/5/2020 |
| Split Ratio | 18:1 |
Scores
Eledon Pharmaceuticals, Inc. posts an Altman Z-Score of -6.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.93 |